search
Back to results

Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing After Total Knee Arthroplasty (TKA)

Primary Purpose

Knee Osteoarthritis

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
SOLUGEL
Placebo
Sponsored by
University of Arkansas
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Knee Osteoarthritis focused on measuring collagen peptides, TKA, osteoarthritis, connective tissue

Eligibility Criteria

50 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Males and Females, 50 to 75 years old With a body mass index of 20.0 to 39.9 kg/m2 Diagnosed with primary osteoarthritis Scheduled for a TKA at UAMS (two months prior to surgery) at UAMS Live near Little Rock and scheduled to attend physical therapy in Little Rock COVID-19 negative and/or asymptomatic. Exclusion Criteria: Previously sustained serious knee injury or surgery to ACL in TKA knee Females not postmenopausal Having undergone hormone replacement therapy in the last 12 months. Active diagnosis of blood borne infectious disease

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Collagen Peptides

    Placebo

    Arm Description

    10 grams per day for 24 weeks

    10 grams per day maltodextrin for 24 weeks

    Outcomes

    Primary Outcome Measures

    Effects of pre-surgical supplementation on mRNA transcription
    Measuring mRNA in the anterior cruciate ligament extracted during surgery

    Secondary Outcome Measures

    Full Information

    First Posted
    April 10, 2023
    Last Updated
    October 6, 2023
    Sponsor
    University of Arkansas
    Collaborators
    Tessenderlo Group
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05823727
    Brief Title
    Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing After Total Knee Arthroplasty (TKA)
    Official Title
    Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing After Total Knee Arthroplasty (TKA)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    December 1, 2023 (Anticipated)
    Primary Completion Date
    June 1, 2024 (Anticipated)
    Study Completion Date
    June 1, 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University of Arkansas
    Collaborators
    Tessenderlo Group

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Recruiting will be performed via checking the calendar for scheduled TKA procedures in the > 8 weeks by clinical staff in the UAMS orthopedic clinic. Clinic staff will look for basic inclusion/exclusion criteria in the EMR for those patients. Clinic staff will either contact directly or send contact information to the PI of this study to contact for recruitment purposes. During the initial phone call, study staff will review inclusion/exclusion criteria to verify eligibility and will discuss study specifics and send a link to the current informed consent form located on the UAMS REDCap server. If the subject wishes to enroll, they will do so via electronic consent through REDCap. REDCap will notify study staff that the consent was signed, then study staff will schedule initial baseline study visit. Visit 1 and Visit 2 will take place at the RIOA at week 0 and week 24, respectively. Participants will report having fasted overnight, and having abstained from alcohol for 24 hours, vigorous exercise for 24 hours, and caffeine for 12 hours. A blood sample will be drawn upon arrival, followed by a DXA scan to measured bone mineral density (BMD) in both hips and lumbar spine, and for body composition, using CTRAL equipment. Participants will also undergo a body water assessment using BIA to determine deuterium dose. Bilateral handgrip strength will be measured via Dynamometer. Participants will fill out a 3-Day food log, physical activity questionnaire, pain scale, KOOS, VR-12, and the POMS. Participants will be given an 8-week supply of their respective treatment supplement, with instructions and a compliance log (to be filled out monthly). Participants will also be given their dose of deuterium oxide (D2O) to be ingested according to instruction at week 2&3, prior to TKA (week 4). Tissue samples for ACL, bone fragments, and synovial fluid will be collected by the PI during TKA surgery. All other assessments will be taken during clinical visits with the participant's physical therapists and their orthopedic doctors. The PI will attend some of these visits to assess wound healing, administer handgrip strength assessment, and to replenish participant treatment supply.
    Detailed Description
    UAMS Orthopedic Clinic personnel will monitor the clinic logs for prospective participants meeting the inclusion/exclusion criteria of the study, notifying the study Principal Investigator (PI) of potential study participants. The PI will meet with the with interested participant to obtain consent virtually (via REDCap) prior to scheduling baseline visit (week 0) at the UAMS Reynolds Institute on Aging (RIOA). The potential study participant will be allowed as much time as needed to be comfortable in their decision to participate in the study. For tissue specimen collection during TKA, the PI will attend the surgery, collecting samples of the ACL, synovial fluid and bone fragments as they are removed (and would otherwise be discarded) by the surgeon. Blood will also be collected by the anesthesiologist after line placement in the operating room. Tissue samples will be prepared as described in the Specimen Handling and Storage Section and taken to the PI's laboratory, the Center for Translational Research in Aging and Longevity (CTRAL) located on the 7th floor of the UAMS RIOA (a secured access floor). Study Visits Week 0 (Baseline) Informed Consent (executed electronically) Randomization (Excel Randomization Function) Baseline assessments (CTRAL) Knee Injury and Osteoarthritis Outcome Score (KOOS) Veterans RAND 12 (VR-12) Profile of Mood States (POMS) Physical Activity Pain Dietary Intake (3-Day Food Log) Dual-energy X-ray absorptiometry (DXA) scan - bone density (both hips and lumbar spine) Dual-energy X-ray absorptiometry (DXA) scan - body composition Bioelectrical impedance analysis (BIA) Scan - body water Hand grip strength Collecting blood sample (4 mL x 1 for serum and 4 mL x 1 for plasma) Treatment 10 g Collagen Peptides or Placebo, Weeks 0 - 24 Deuterated water (D2O), Weeks 6 - 8 Week 4 Virtual Knee Injury and Osteoarthritis Outcome Score (KOOS) Veterans RAND 12 (VR-12) Profile of Mood States (POMS) Physical Activity Pain 3-day food log Compliance Week 8 Virtual Knee Injury and Osteoarthritis Outcome Score (KOOS) Veterans RAND 12 (VR-12) Profile of Mood States (POMS) Physical Activity Pain 3-day food log Compliance Total Knee Arthroplasty Collect Anterior Cruciate Ligament Collect Synovial Fluid Collect blood sample (4 mL x 1 for serum and 4 mL x 1 for plasma) Physical Therapy (three times weekly, Weeks 8 - 24) Pain Range of Motion (ROM) for flexion and extension of surgery knee KOOS Jr. Week 10 Physician Visit Wound healing Pain ROM for flexion and extension of surgery knee Grip Strength Week 12 Virtual Knee Injury and Osteoarthritis Outcome Score (KOOS) Veterans RAND 12 (VR-12) Profile of Mood States (POMS) Physical Activity Pain 3-day food log Compliance Week 14 Physician Visit Wound healing Pain ROM for flexion and extension of surgery knee Grip Strength Week 16 Virtual Knee Injury and Osteoarthritis Outcome Score (KOOS) Veterans RAND 12 (VR-12) Profile of Mood States (POMS) Physical Activity Pain 3-day food log Compliance Physical Therapy Follow Up Pain ROM KOOS Jr. Functional Measures Battery Week 20 Virtual Knee Injury and Osteoarthritis Outcome Score (KOOS) Veterans RAND 12 (VR-12) Profile of Mood States (POMS) Physical Activity Pain 3-day food log Compliance Physician Visit Wound healing Pain ROM for flexion and extension of surgery knee Grip Strength Week 24 (Final Assessments - Stop Treatment) CTRAL Knee Injury and Osteoarthritis Outcome Score (KOOS) Veterans RAND 12 (VR-12) Profile of Mood States (POMS) Pain Activity DXA - bone mineral density (both hips and lumbar spine) DXA - body composition Grip Strength Compliance 3-Day Food Log

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Knee Osteoarthritis
    Keywords
    collagen peptides, TKA, osteoarthritis, connective tissue

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    Placebo controlled clinical trial.
    Masking
    ParticipantInvestigator
    Masking Description
    Double blind
    Allocation
    Randomized
    Enrollment
    44 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Collagen Peptides
    Arm Type
    Experimental
    Arm Description
    10 grams per day for 24 weeks
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    10 grams per day maltodextrin for 24 weeks
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    SOLUGEL
    Other Intervention Name(s)
    CP
    Intervention Description
    Bovine collagen peptide supplement
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Placebo
    Intervention Description
    Maltodextrin
    Primary Outcome Measure Information:
    Title
    Effects of pre-surgical supplementation on mRNA transcription
    Description
    Measuring mRNA in the anterior cruciate ligament extracted during surgery
    Time Frame
    2 months after supplementation

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    50 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Males and Females, 50 to 75 years old With a body mass index of 20.0 to 39.9 kg/m2 Diagnosed with primary osteoarthritis Scheduled for a TKA at UAMS (two months prior to surgery) at UAMS Live near Little Rock and scheduled to attend physical therapy in Little Rock COVID-19 negative and/or asymptomatic. Exclusion Criteria: Previously sustained serious knee injury or surgery to ACL in TKA knee Females not postmenopausal Having undergone hormone replacement therapy in the last 12 months. Active diagnosis of blood borne infectious disease

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing After Total Knee Arthroplasty (TKA)

    We'll reach out to this number within 24 hrs